MiNK Therapeutics Q2 FY26 net loss narrows to $3.13 million; cash falls to $8.81 million
Reuters2026/08/13 11:31- Mink Therapeutics posted a Q2 net loss of USD 3.13 million, narrowing from USD 4.24 million a year earlier.
- Loss per share improved to USD 0.62 from USD 1.06 in the prior-year quarter.
- Cash and cash equivalents fell to USD 8.81 million at June 30 from USD 13.36 million at Dec. 31.
- Cash used in operations rose to USD 2.08 million from USD 1.57 million a year earlier.
- Randomized Phase 2 C-1300-02 trial in acute lung injury initiated in May; initial Day 28 observations showed survival and improved oxygenation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Delta Electronics (Thailand)'s Recent Selloff Presents Accumulation Opportunity -- Market Talk
The data center construction boom may increase inflationary pressure, and the Reserve Bank of Australia may be forced to maintain high interest rates.
The data center construction boom in Australia may lead to demand exceeding the supply capacity of the economy, which could push up inflation and force the Reserve Bank of Australia to maintain higher interest rates.
Reliance step-down unit Roptonal dissolves in Cyprus with effect Aug. 18, 2026
Crypto prices
More
